The second major factor has been the convening of large international consortia comprised of individual groups, which together have resulted in samples of tens of thousands of cases and controls.3 This has resulted from the realization that the small effect sizes of most common variants can only be detected using very large Ns, which could never be obtained in any single study. Schizophrenia has been one of the main beneficiaries of these advances. For the first time, numerous genetic markers have been reliably associated with illness across multiple populations. The Psychiatric Genomics Consortium (PGC) Schizophrenia Workgroup has by now amassed most of the existing GWAS samples in the field and continues to grow.4 The most recent “mega-analysis” has resulted in the identification of >100 significantly associated loci, of which 75% included protein